[Edaily Reporter Kim Seung-kwon ] On the 30th, Helixmith Co., Ltd(084990)rose nearly 20% on expectations of royalties from the commercialization of a gene therapy by its Chinese partner, while Genome&Company(314130)posted double-digit gains as anticipation of a technology transfer grew ahead of a global antibody-drug conjugate (ADC) conference next month. #SGHEALTHCARE CO.,LTD. rose 13% on news of an exclusive domestic business rights agreement with a Chinese particle therapy company. All three stocks had seen their share prices fall significantly over the past year.

Helixmith Co., Ltd: “Sedomingi,” the fruit of 22 years of perseverance, to be commercialized in China… Expectations for royalty inflows

According to KG Zeroin, Helixmith Co., Ltd closed at 3,815 won, surging 18.85% (605 won) from the previous trading day. The stock soared as high as 4,170 won during the session, driven by strong buying momentum.

Over the past year, Helixmith Co., Ltd’s stock price has experienced extreme volatility, marked by alternating periods of optimism and disappointment. This past spring, as anticipation grew for a marketing authorization from its Chinese partner, the stock briefly touched the 8,000-won range (52-week high of 9,960 won). However, immediately after the actual approval news was announced last May, the stock price reversed course and fell to the 2,700-won range, driven by profit-taking following the news and concerns over initial market entry uncertainties.

Today’s stock price rebound was driven by renewed expectations of generating substantial royalty cash flow, as the commercialization of “Sedomingji Injection (NL003),” a treatment for critical limb ischemia (CLI) developed through HelixSmith’s Chinese partner Northland Biotech, is imminent. Sedomingji was developed based on Helixmith Co., Ltd.’s gene therapy “Engensis (VM202)” and received marketing approval from China’s National Medical Products Administration (NMPA) last May as China’s first plasmid DNA-based gene therapy. Northland officially announced its commercial launch at the China Cell & Gene Therapy Conference (CSGCT 2026) held recently in Beijing.

This achievement comes a full 22 years after the technology transfer in 2004. Helixmith Co., Ltd will receive royalties for seven years following market launch, amounting to the higher of 7% of net sales or 4% of total sales each year. The company’s financial turnaround is also positive. Since Bio Solution Co.,Ltd. became the largest shareholder in late 2023, the company has implemented rigorous restructuring, significantly reducing its net loss from 64.1 billion won (in 2023) to approximately 300 million won last year, while also securing a solid cash reserve of about 80 billion won.

The key challenge is establishing a foothold in the local market. A securities analyst noted, “The 25% plunge in Northland’s stock price on the day of approval was driven by concerns over the limitations of non-reimbursed prescriptions and barriers to hospital access,” adding, “Whether Helixmith Co., Ltd. succeeds in getting its drug listed on China’s National Medical Insurance Drug List—a process currently underway—will be a decisive factor in the company’s enterprise value.”

A Helixmith Co., Ltd official emphasized, “Using the global reference of the NL003 approval as leverage, we plan to fully launch technology transfers, joint development, and strategic partnerships in global markets outside of China.”

Genome&Company Prepares to Launch ‘World ADC’… Setting Sights on Technology Transfer for Next-Generation Targets

Genome&Company closed at 5,100 won, up 13.59% (610 won) from the previous trading day. Following a 14% surge on the 23rd, the stock has continued its upward rally; the share price, which hovered in the mid-3,000 won range earlier this month, has risen by nearly 50% over the past month. However, it remains at about half the level of its 52-week high of 10,180 won.

The catalyst for the stock’s rally is the news of the company’s participation in “World ADC,” the world’s largest conference dedicated to ADCs, to be held in San Diego, U.S., from November 12 to 15. At the event, the company plans to unveil key research data on its new ADC pipeline—targets identified through its proprietary drug discovery platform, “GNOCLE”—and engage in full-scale technology transfer (L/O) discussions with multiple multinational pharmaceutical companies.

Genome&Company’s competitive edge lies in its ability to secure “novel targets” first. While existing ADC anticancer drugs are primarily focused on targets such as HER2 and TROP2, Genome&Company is seeking to differentiate itself with products like “GENA-104 ADC,” which targets contactin-4 (CNTN4), and “GENA-120,” which targets integrin β4 (ITGB4).

In particular, ‘GENA-120’ is designed with a highly efficient ‘DAR 8’ structure—featuring eight payloads attached to a single antibody—and is expected to demonstrate superior anticancer efficacy compared to its competitor, China’s Cistone’s CS5006 (DAR 4).

Secures

Exclusive Rights in Korea for China’s Kasim “Triple-Particle Therapy Device”… A Paradigm Shift in Medical Devices

SGHEALTHCARE CO.,LTD. closed at 2,305 won, up approximately 13% from the previous trading day. The stock price, which had been stuck in a sluggish sideways trend in the 1,900-won range until mid-month, surged above the 2,300-won mark in one fell swoop following news of securing exclusive rights to major overseas equipment.

The direct catalyst for SGHEALTHCARE CO.,LTD.’s stock price surge is its entry into the “particle therapy” market—a field of ultra-precise radiation therapy characterized by extremely high barriers to entry. On the 29th, the company announced that it had signed an agreement on the 28th with CASHIM, a Chinese company specializing in particle therapy, for the exclusive domestic supply of the next-generation “Triple Particle Therapy System” and strategic business cooperation. Through this agreement, SGHEALTHCARE CO.,LTD. will provide major domestic hospitals with a total solution—ranging from business development, installation support, technical training, and maintenance—that goes beyond the simple delivery of equipment.

CASHIM’s “HiTS 200,” for which SG Healthcare has secured exclusive rights, is hailed as a game-changer in the clinical field. It is a state-of-the-art system capable of generating as many as three different types of particle beams—proton, helium ion, and carbon heavy-ion beams—on a single accelerator platform. In particular, while the construction of existing heavy-ion therapy centers required vast tracts of land and investments of hundreds of billions of won, the HiTS 200 can be installed in a relatively compact space of approximately 1,500 square meters, maximizing space and cost efficiency.

Kasim is a small-to-medium-sized enterprise established as a spin-off of the Institute of Modern Physics at the Chinese Academy of Sciences, leveraging its unrivaled research achievements in heavy-ion accelerators. The company obtained approval to sell medical accelerators as early as 2019. With five treatment systems currently operational in China and plans to install nine more by 2031, the commercial viability of the technology has been proven.

Kim Jeong-su, CEO of SGHEALTHCARE CO.,LTD., emphasized, “This exclusive agreement marks a crucial starting point for popularizing next-generation particle therapy technology in the domestic healthcare sector,” adding, “We will provide integrated solutions optimized for the domestic healthcare environment and comprehensively expand our business scope into a high-value-added next-generation cancer treatment platform through integration with our core strength—AI image analysis technology.”

Meanwhile, ABION Inc. announced that it had signed a joint research and technology licensing agreement with LigaChem Biosciences regarding an immunocytokine-antibody-drug conjugate (iADC) platform. By applying LigaChem Biosciences’ ADC platform technology to ABION Inc.’s interferon beta mutant (IFN-β mutein)-based immunocytokine-antibody, the two companies have created a single combined molecule, through which LigaChem Biosciences has secured global exclusive development and commercialization rights for up to five targets. Although the terms of the agreement were not disclosed, the deal is valued at more than 10% of LigaChem Biosciences’s equity capital (541.1 billion won).

However, on the same day, the Korea Exchange (KRX) decided to subject ABION Inc. to a substantive review of its listing eligibility pursuant to Article 56, Paragraph 1 of the KOSDAQ Market Listing Regulations. Consequently, trading in ABION Inc.’s shares remains suspended, and the KRX plans to decide, following a review by the Corporate Review Committee within 20 business days from the date of notification—by October 30—whether to delist the company or grant it a period for improvement.